Share on StockTwits

Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Peter Mueller sold 7,500 shares of the company’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $67.45, for a total transaction of $505,875.00. Following the completion of the transaction, the executive vice president now directly owns 143,517 shares of the company’s stock, valued at approximately $9,680,222. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Vertex Pharmaceuticals (NASDAQ:VRTX) traded down 0.66% on Friday, hitting $65.03. 2,018,828 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 1-year low of $58.06 and a 1-year high of $89.96. The stock’s 50-day moving average is $66.57 and its 200-day moving average is $72.28. The company’s market cap is $15.360 billion.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.65) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.68) by $0.03. The company had revenue of $118.50 million for the quarter, compared to the consensus estimate of $134.46 million. During the same quarter in the prior year, the company posted $0.03 earnings per share. The company’s quarterly revenue was down 63.9% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $-2.88 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at TheStreet downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 6th. Separately, analysts at Zacks upgraded shares of Vertex Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Tuesday, April 22nd. They now have a $68.20 price target on the stock. Finally, analysts at Ned Davis Research upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $87.69.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.